Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP2 | O95551 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 5/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 4/20 | 0.35 |
| ▸ | BRD1 | O95696 | 3/20 | 0.35 |
| ▸ | BRPF3 | Q9ULD4 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710142 | 0.89 | ROCK2 (0.41) | ROCK2GRM4TRPA1ROCK1 | |
| SCHEMBL6710017 | 0.88 | RXFP1 (0.45) | TDP2ROCK2BRPF1GRM4ROCK1 | |
| SCHEMBL6713418 | 0.88 | RXFP1 (0.36) | ROCK2TNIKBRPF1GRM4ROCK1 | |
| SCHEMBL6710299 | 0.86 | BRD4 (0.42) | ROCK2BRD4 | |
| SCHEMBL6709982 | 0.86 | MAPT (0.38) | NR3C2 | |
| SCHEMBL6710229 | 0.86 | NAMPT (0.40) | ROCK2PGRBRD4GRM4ROCK1 | |
| SCHEMBL6708716 | 0.85 | ROCK2 (0.40) | ROCK2GRM4ROCK1 | |
| SCHEMBL7159445 | 0.85 | ROCK2 (0.40) | ROCK2BRD4GRM4 | |
| SCHEMBL6711975 | 0.85 | TRPA1 (0.46) | ROCK2GRM4TRPA1ROCK1 | |
| SCHEMBL6708021 | 0.84 | MAPT (0.41) | TDP2ROCK2TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | disclosed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | TDP2 3788/4885ROCK2 4868/4885PGR 3743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.